Clopidogrel response in ischemic stroke patients: Is polymorphism or gender more important? Results of the CRISP study |
| |
Institution: | 2. Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China;3. China National Clinical Research Center for Neurological Diseases, Beijing, China;4. Center of Stroke, Beijing Institute for Brain Disorders, Beijing, China;6. Beijing Key Laboratory of Translational Medicine for Cerebrovascular Disease, Beijing, China;5. Department of information engineering, Tangshan vocational and technical college, Tangshan, China |
| |
Abstract: | Clopidogrel (CLP) is a second generation thienopyridine drug commonly used in secondary prevention of ischemic stroke (IS). Its antiplatelet response maybe variable due to genetic and non-genetic factors. Adipokines may affect platelet aggregation through ADP mediated platelet signalling. However, the combined effect of CYP genetic variants and adipokines on antiplatelet response of clopidogrel is unclear. Patients of IS/Transient ischemic attack (TIAs) within 3 months were prospectively screened following clopidogrel treatment. Major exclusions were cardioembolic and non atherosclerotic strokes. Antiplatelet effect of clopidogrel along with adipokine (Leptin and adiponectin) levels and genotyping of CYP, P2Y12 gene were investigated. Rare genetic variants were confirmed by DNA sequencing. 204 patients with ischemic stroke/TIAs were screened and 163 were recruited. 85 (52.1%) patients were poor responders to clopidogrel. Antiplatelet response to clopidogrel was weaker in females Median 8.0 (IQR: 3.0–14.0)] compared to males Median 5.0 (IQR: 2.0–10.0)]. In female subgroup analysis, association was found among high leptin levels and PPI (+) usage in poor responders. None of the genetic variants (CYP2C19*2,*3,*4*, CYP2C9*3, CYP2B6 and P2Y12) were found to influence the antiplatelet effects (p > 0.05). On multivariable logistic regression, a poor clopidogrel response was associated with female gender (Adjusted OR 2.55, 95% CI: 1.05–6.18) and PPI usage (Adjusted OR 2.42, 95% CI: 1.09–5.34). Despite a high prevalence of clopidogrel resistance in the North Indian stroke patients, female gender rather than genetic polymorphisms of CYP and P2Y12 genes may influence its antiplatelet effect. Further research may ascertain the role of gender on clopidogrel response. |
| |
Keywords: | Anti-platelet effect Clopidogrel CYP Ischemic stroke P2Y12 |
本文献已被 ScienceDirect 等数据库收录! |
|